APCCC 2022 | ADT monotherapy for treatment of metastatic hormone-sensitive disease

Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, discusses the clear consensus reached at the Advanced Prostate Cancer Consensus Conference (APCCC) that androgen deprivation therapy (ADT) should not be used as a monotherapy in the majority of patients with metastatic hormone-sensitive disease, and instead should be used in combination with other forms of therapy. This interview took place at the APCCC 2022 conference, held in Lugano, Switzerland.